Clonal Cytopenia of Undetermined Significance (CCUS)

2

Review clinical trials related to Clonal Cytopenia of Undetermined Significance (CCUS). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

CHIP in Health and Disease

Clonal hematopoiesis (CH), including clonal hematopoiesis of indeterminate potential (CHIP), is an age-associated condition characterized by the expansion of hematopoietic stem and progenitor cell clones carrying acquired somatic mutations. Although CH is associated with an increased risk of hematologic malignancies, its greater public health impact derives from its strong association with cardiovascular diseases, including coronary artery disease and stroke. Emerging evidence suggests that CH-associated mutations promote chronic inflammatory signaling in myeloid immune cells, thereby contributing to atherosclerosis and adverse cardiovascular remodeling. This observational translational study aims to characterize the biological spectrum of clonal hematopoiesis across different stages of disease risk and manifestation. Using state-of-the-art single-cell and multi-omics approaches, the study will compare inflammatory pathways, immune cell states, and mutation-associated molecular programs among healthy individuals without CH, individuals with high-risk CH, and patients with CH-associated hematologic or cardiovascular disease. The ultimate goal is to identify shared and disease-specific mechanisms linking clonal hematopoiesis to adverse clinical outcomes and to generate insights for future preventive, anti-clonal, and anti-inflammatory therapeutic strategies.

Participants needed: 120
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: VASCage GmbHUpdated: Aug 21, 2026Locations: 1
Eligibility criteria

Written informed consent has been obtained for participation in the study "Decon... [+40]

Treatment with immunosuppressive medication within the previous 4 weeks, includi... [+1]

Status: Not yet recruiting

Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation

This study will test a study drug called REGN17235 (the "study drug") to see if it can help treat Clonal Cytopenia of Undetermined Significance (CCUS) and Low-Risk Myelodysplastic Syndrome (LR-MDS) with a specific genetic mutation (SF3B1 Mutation). The study is looking at: * What side effects the study drug might cause * How well the study drug works * How much of the study drug is in the blood at different times * If the body makes antibodies (proteins that attach to substances your body does not recognize) against the study drug; this may cause the study drug to not work as well. * What is the best dose of the study drug to treat CCUS and LR-MDS

Participants needed: 52
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Regeneron PharmaceuticalsUpdated: Aug 7, 2026
Eligibility criteria

Presence of SF3B1 mutation in the bone marrow or peripheral blood AND diagnosis... [+2]

Clinically significant anemia due to non-MDS or non-CCUS etiologies (eg, iron de... [+4]